GlassScriptPhysician profile
Diane T Pace
NPI 1518953553
$41,924.47
in general payments reported to CMS, 2019-2025
14 companies · $4,939 in 2025
The $4,939 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,924 · 2022: $7,283 · 2023: $23K · 2024: $4,623 · 2025: $4,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $5,826 · Food and Beverage: $2,565 · Honoraria: $2,525 · Consulting Fee: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,370.00 |
| Travel and Lodging | $5,825.64 |
| Food and Beverage | $2,565.14 |
| Honoraria | $2,525.00 |
| Consulting Fee | $1,432.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31,282.78 | 2022-2024 | Veozah |
| Mayne Pharma Commercial LLC | $3,528.84 | 2022-2025 | |
| Shield Therapeutics INC | $2,649.29 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $1,923.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,577.01 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $274.42 | 2024 | Gemtesa, Myfembree |
| Avion Pharmaceuticals | $219.85 | 2022 | |
| Novo Nordisk INC | $171.76 | 2023-2024 | Wegovy |
| Astellas Pharma Global Development | $156.35 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $45.51 | 2022 | |
| Scynexis, INC. | $33.20 | 2022 | |
| Biogen, INC. | $28.80 | 2023 | |
| Pfizer INC. | $18.13 | 2023 | |
| Masimo Corporation | $14.87 | 2024 | Set and Rainbow Set |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.